Veru anticipates filing a new IND for sabizabulin to address inflammation in atherosclerotic cardiovascular disease, with Phase 2 studies using coronary CT angiography as the primary endpoint.

Short interest in Veru Inc (NASDAQ:VERU) decreased during the last reporting period, falling from 15.00M to 13.71M. This put 10.48% of the company's publicly available shares short. Short interest ...